CYCL yields 5449.59% · MRK yields 2.81%● Live data
📍 CYCL pulled ahead of the other in Year 1
Combined, CYCL + MRK cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CYCL + MRK for your $10,000?
Cycclone Inc., together with its subsidiaries, engages in the production, marketing, and distribution of bacteria based products used as additives for livestock feed and crop cultivation in the People's Republic of China. It provides artificial microorganisms (AM) and high-efficiency microorganism (HM) based biological bacterium blends; and biological preservatives. The company offers AM/HM bacteria based additives for crops, including Bulgaria lactobacillus, beer microzyme, and dark red spirilla used to increase the beneficial microorganism colonies in soil; inhibit the reproduction of harmful fungi and putrefactive bacteria; and to improve nutrient absorption and reduce crop and livestock diseases. It also provides AM/HM bacteria based additives for livestock feed, which softens the livestock feed and restrain the growth and reproduction of pathogenic bacteria, as well as supplies beneficial nutriments, including organic acid, vitamins, enzyme, antibiotics, mycelium protein, and other growth-enhancing substances that balance the nutrients in the feed. In addition, the company offers FGW bacterial based preservatives that preserve animal specimens for scientific research; and preserve the freshness for agricultural produce. Further, it provides bacteria based fertilizer for application on plants, such as vegetable and fruit leaves. Additionally, the company engages in residential and commercial real estate investment. The company was formerly known as China Dasheng Biotechnology Co. and changed its name to Cycclone Inc. in May 2025. Cycclone Inc. was founded in 2004 and is based in Lanzhou, China.
Full CYCL Calculator →Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Full MRK Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.